Douglas Kahn, CEO of Tetragenetics Inc., told BioWorld that his firm "in pretty short order went from introducing the technology to discussing the terms of a potential relationship" for the purpose of developing non-opioid pain drugs with Imbrium Therapeutics LP, a subsidiary of Purdue Pharma LP, the embattled maker of Oxycontin (oxycodone).